An international team of researchers has identified DNA mutations in a gene that senses viral RNA, as a cause of the autoimmune disease lupus, with the finding paving the way for the development of new treatments.
Drug that restricts over active immune system could help treat lupus
Malaria research advances immunotherapy in lupus
A discovery about how the immune system responds to malaria infection could lead to better treatments for hepatitis C, HIV and lupus. The research showed, in laboratory models, that strong inflammatory signals caused by malaria infection activate molecules that trigger B cells to produce highly potent antibodies to fight the disease.
Groundbreaking genetic discovery shows why Lupus develops
Resunab, a promising future treatment for lupus.
Patent holder Corbus Pharmaceuticals is putting the drug, branded Resunab, through its clinical paces.
Ajulemic acid (AJA, CT‐3, IP‐751, JBT‐101, anabasum) is a first‐in‐class, synthetic, orally active, cannabinoid‐derived drug that preferentially binds to the CB2 receptor and is non psychoactive.
In preclinical studies, and in Phase 1 and 2 clinical trials, AJA showed a favorable safety, tolerability, and pharmacokinetic profile. It also demonstrated significant efficacy in preclinical models of inflammation and fibrosis.
